Erasca, Inc. ERAS
At Erasca, our name is our mission: to erase cancer.
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. Our focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment. Our pipeline enables us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| SG&A | $38.6M | $41.7M | $37.7M | $33.0M | $22.6M | $8.0M | — |
| Total operating expenses | $140.9M | $179.6M | $141.5M | $247.4M | $124.9M | $109.3M | — |
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M | -$109.3M | — |
| Pre-tax income | -$124.5M | -$161.7M | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M | -$101.7M | — |
| EPS, basic | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | — | — |
| EPS, diluted | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | -4.83 | — |
| Shares, diluted (wtd. avg.) | 283.5M | 233.8M | 150.2M | 122.0M | 66.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $73.8M | $67.7M | $93.1M | $284.2M | $360.5M | $65.4M | — |
| Short-term investments | $202.3M | $230.6M | $219.3M | $151.4M | $54.0M | $53.3M | — |
| Total current assets | $286.2M | $308.8M | $320.7M | $444.5M | $420.0M | $120.0M | — |
| Property, plant and equipment | $13.3M | $16.3M | $22.3M | $24.8M | $16.0M | $1.8M | — |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M | $124.8M | — |
| Accounts payable | $981.0K | $468.0K | $2.0M | $23.0M | $4.7M | $878.0K | — |
| Total current liabilities | $28.5M | $31.4M | $26.2M | $48.7M | $26.2M | $13.7M | — |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M | $17.4M | — |
| Retained earnings | -$892.2M | -$767.7M | -$606.0M | -$481.0M | -$238.2M | -$115.4M | — |
| Total equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M | -$114.0M | -$13.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M | -$32.7M | — |
| Depreciation and amortisation | $3.1M | $3.8M | $3.7M | $2.6M | $829.0K | $540.0K | — |
| Stock-based compensation | $24.9M | $27.0M | $26.2M | $20.1M | $8.3M | $797.0K | — |
| Capital expenditure | $128.0K | $60.0K | $1.8M | $14.6M | $11.2M | $947.0K | — |
| Investing cash flow | $100.4M | -$156.6M | -$91.2M | -$71.1M | -$64.6M | -$71.2M | — |
| Financing cash flow | $1.1M | $240.7M | $1.3M | $98.1M | $439.4M | $140.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104150.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$101.7M | -$122.8M | -$242.8M | -$125.0M | -$161.7M | -$124.5M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |